Does tranexamic acid reduce risk of mortality on patients with hemoptysis?
A protocol for systematic review and meta-analysis

Liang-Fu Chen, MDa,b, Ting-Cheng Wang, MDa,b, Ting-Yi Lin, MDa,b, Po-Jia Pao, MDa,b, Karen Chia-Wen Chu, MDa,b, Chih-Hao Yang, MDa,b, Jer-Hwa Chang, MDb,c,d,e, Chin-Wang Hsu, MDa,b, Chyi-Huey Bai, PhDF, Yuan-Pin Hsu, MDa,b,g,∗

Abstract
Background: Although tranexamic acid (TXA), a readily accessible antifibrinolytic agent, is widely adopted in hemorrhage scenarios, its role on mortality in patients with hemoptysis remains uncertain. New evidence is yet to be generated to evaluate the risk of mortality after using TXA in patients with hemoptysis.

Methods: PubMed, EMBASE, Cochrane Library, Web of Science, and Scopus databases were searched from inception to May 2020. Randomized controlled trials and observational studies that evaluated the effect of TXA on patients with hemoptysis were included. Data were independently extracted by 2 reviewers and synthesized using a random-effects model.

Main results: Five studies with a total of 20,047 patients were analyzed. When compared with the control, administration of TXA was associated with a reduction in short-term mortality (risk ratio = 0.78, 95% confidence interval [CI] 0.72–0.85; I² = 0), shorter bleeding time (mean difference = −24.61 hours, 95% CI −35.96 to −13.26, I² = 0), shorter length of hospital stay (mean difference = −1.94 days, 95% CI −2.48 to −1.40, I² = 0), and lower need for intervention (risk ratio = 0.38, 95% CI 0.16–0.87, I² = 0) in patients with hemoptysis. Compared with control, administration of TXA did not cause increased major or minor adverse effects.

Conclusions: TXA provided benefits in terms of a lower short-term mortality rate, less bleeding time, shorter length of hospital stays, and less need for intervention in patients with hemoptysis. Use of TXA was not associated with increased adverse effects.

Abbreviations: CI = confidence interval, IV = intravenous, MD = mean difference, RCT = randomized controlled trial, RR = risk ratio, TXA = tranexamic acid

Keywords: hemoptysis, mortality, tranexamic acid

1. Introduction
Hemoptysis, which can result from various etiologies, with malignancy, pulmonary infection, and bronchiectasis listed as the 3 leading causes, remains a challenging condition for physicians.[1] The clinical manifestations range from a nonalarming bloody expectoration to a life-threatening bleeding condition. Approximately 5% to 14% of patients presenting with hemoptysis will have life-threatening hemoptysis,[2] with a reported mortality rate between 9% and 38%.[3] The amount of blood expectorated may be associated with in-hospital mortality.[4] Additionally, a recent French nationwide study indicated that 9.0% of patients who were hospitalized for hemoptysis required admission to the intensive care unit.[5] The reported average length of hospital stay among these patients is

Editor: Shreedhar Kulkarni.
L-FC and T-CW contributed equally to this study.
Funding: The authors received financial support from project no. 109-wf-eva-19 of Wan Fang Hospital, Taipei Medical University, Taiwan.
The authors report no conflicts of interest.
This manuscript was edited by Wallace Academic Editing.
Supplemental Digital Content is available for this article.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].
aEmergency Department, Wan Fang Hospital, bDepartment of Emergency Medicine, School of Medicine, cSchool of Respiratory Therapy, College of Medicine, dDivision of Pulmonary Medicine, Department of Internal Medicine, ePulmonary Research Center, Wan Fang Hospital, fDepartment of Public Health, School of Medicine, College of Medicine, Research Center of Big Data and Meta-Analysis, wan fang hospital, Taipei Medical University, Taipei, Taiwan.
∗Correspondence: Yuan-Pin Hsu, Emergency Department, Wan Fang Hospital, Taipei Medical University, No. 111, Sec. 3, Xinglong Rd., Taipei 11696, Taiwan (e-mail: koakoahsu@gmail.com)

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Chen LF, Wang TC, Lin TY, Pao PJ, Chu KC, Yang CH, Chang JH, Hsu CW, Bai CH, Hsu YP. Does tranexamic acid reduce risk of mortality on patients with hemoptysis? A protocol for systematic review and meta-analysis. Medicine 2021;100:20(e25898).
Received: 7 January 2021 / Received in final form: 23 April 2021 / Accepted: 23 April 2021
http://dx.doi.org/10.1097/MD.0000000000025898
blood, amount of blood loss, need for intervention, length of hospital stay, and recurrence rate. Safety outcomes were major adverse events, such as venous thromboembolism, coronary artery occlusion, and stroke, which were attributable to the mechanism of action of TXA, and minor adverse events, such as nausea, dizziness, vomiting, abdominal pain, and diarrhea.

2.3. Data extraction and management

Two reviewers (LFC and CHY) independently extracted the data. The following information was extracted: first author, publication year, country, study design, sample sizes, inclusion and exclusion criteria, baseline characteristic, regimens of each intervention, and data of the outcome interest. Any controversies regarding recorded data were resolved through discussion between the authors or by consulting a third reviewer (YPH).

2.4. Assessment of risk of bias

Two investigators (TYL and PJP) independently assessed the methodological qualities of the included studies. The Cochrane risk of bias tool 2.0 for RCTs was used. This tool includes 6 domains: selection bias due to the inadequate generation of a randomized sequence or concealment of allocation before the assignment, performance bias due to the knowledge of allocated interventions by participants and personnel, detection bias due to the knowledge of allocated interventions by outcome assessors, reporting bias due to selective outcome reporting, and other biases. The Newcastle–Ottawa scale tool was applied to assess the quality of observational studies. Studies were evaluated by selection with a maximum of four stars, comparability with a maximum of 2 stars, and outcome with a maximum of three stars. Studies with cumulative stars >7 were considered to be of high quality. If no agreement could be reached, a third investigator (YPH) determined the rating.

2.5. Statistical analysis

Data were analyzed using Review Manager (version 5.3, Copenhagen, Denmark). Meta-analyses were performed using a random-effects model. For binary outcomes, the risk ratio (RR) was estimated with the 95% confidence interval (CI). The mean difference (MD) and 95% CI were used to estimate continuous outcomes. Significant differences between the groups were set at 2-sided P values <.05. Heterogeneities among the studies were estimated using the $I^2$ statistic. The statistical heterogeneity was categorized into low (25%–50%), moderate (50%–75%), or high (>75%) according to the $I^2$ values. In case of substantial heterogeneity, factors that could potentially affect the magnitude of the treatment response were explored using prespecified subgroup analysis (route of administration). To test the robustness of our result of primary outcome, we performed a sensitivity analysis by restricting the meta-analysis of the evidence from only RCTs. If at least 10 studies were included, publication bias was assessed by detecting the asymmetry in funnel plots and using the Egger test.

3. Results

3.1. Study characteristics

The flow diagram of literature search is displayed in Figure 1. In total, 1871 studies were retrieved from different sources, including PubMed, EMBASE, Scopus, the Cochrane Library,
Web of Science, clinicaltrials.gov, and manual search. Subsequently, 630 duplicated records were removed and 1190 articles were excluded after screening titles and abstracts. The full text was then extracted to assess the eligibility. Eventually, 6 and 5 studies were included for qualitative and quantitative analysis, respectively, because Alberto-Pasco and Soto reported the outcome of interest as a composite of mortality and requirement for blood transfusion.\(^{19–24}\)

### 3.2. Study characteristics

The characteristics of the included studies are summarized in Table 1. These studies were conducted in Peru, Thailand, Israel, India, and Japan. Four studies were RCTs, 1 was a retrospective cohort study, and 1 was a case-control study. Five studies enrolled inpatients and 1 study included both inpatients and outpatients. Three studies excluded patients with massive hemoptysis, and the threshold for massive hemoptysis varied among studies. Additionally, 2 RCTs excluded patients with renal failure. Five studies comprised patients with hemoptysis due to all etiologies, and 1 study comprised patients with hemoptysis due to only tuberculosis. Sample sizes ranged from 24 to 19,866 patients, with mean patient ages ranging from 40.1 to 72 years. TXA was administered through inhalation in 1 study, oral route in 1 study, and intravenous (IV) route in 3 studies; 1 study did not provide information regarding the route of administration. The dosage of TXA varied among studies.

### 3.3. Risk of bias assessment

The assessment of risk of bias is shown in Supplementary Table 2, http://links.lww.com/MD/G76. Among RCTs, the study by

---

**Figure 1. Flowchart of article selection process.**
Tscheikuna et al had an unclear selection bias because the randomization protocol was not mentioned. Ruiz found a high risk of attrition bias because they did not perform the intention-to-treat analysis; the reporting bias was evaluated as unclear owing to the lack of protocol disclosed. The remaining 2 RCTs were rated as low-risk bias. For observational studies, 1 study was rated as a high-quality study (scored 8 stars); the study by Alberto-Pasco and Soto was rated as a low-quality study because of limited information regarding population selection, comparability, and exposure details.

3.4. Primary outcome: overall mortality

Three studies (n = 19,937) reported the comparison between the mortality rate when TXA and control were used for the treatment of hemoptysis. TXA was administered through the IV or inhalation route. One study investigated the effect of TXA on in-hospital mortality, 1 on short-term mortality, and 1 on 30-day mortality rate. We regarded these reported outcomes as sharing a similar property of short-term mortality rate. The pooled result indicated that using TXA was associated with reduction in the short-term mortality rate (RR = 0.78, 95% CI 0.72–0.85; Fig. 2). There was no significant heterogeneity between the groups (I² = 0%). A subgroup analysis for patients receiving IV TXA (n = 19,890) also indicated a reduction in short-term mortality (RR = 0.78, 95% CI 0.72–0.85; Fig. 3). Wand et al reported the effect of TXA on long-term mortality. The result showed that using nebulized TXA significantly reduced the 1-year mortality rate compared with the control (n = 47, 16% vs 18%, P < .01). In the sensitivity analysis by excluding evidence from the observational study, the result indicated that TXA led to a lower short-term mortality rate (RR = 0.38, 95% CI 0.10–1.39; Supplementary Figure 1, http://links.lww.com/MD/G71). However, this finding did not reach statistically significant.

3.5. Secondary outcome

3.5.1. Cessation of bleeding. Two studies (n = 93) reported on the cessation of bleeding rate following TXA administration compared with the control. One study evaluated the bleeding status 7 days after oral TXA treatment, and another study evaluated the rate of bleeding resolution 5 days after TXA treatment through nebulization. A total of 41 of 46 (89.1%) patients who received TXA achieved cessation of bleeding, compared with 29 of 47 (61.7%) patients who received the

![Figure 2. Meta-analysis evaluating the short-term mortality rate after tranexamic acid administration.](image-url)
control (RR = 1.44, Table 2, Supplementary figure 2-A, http://links.lww.com/MD/G72). However, the pooled results were not statistically different.

### 3.5.2. Time required to stop bleeding.
Two studies (n = 70) investigated the time in which bleeding stopped after the treatment. In both the studies, TXA was administered systemically; 1 intravenously and 1 orally. Forest plots indicated that compared with patients treated with the control, those treated with TXA had a significantly shorter bleeding time (MD = -24.61 hours, 95% CI = -35.96 to -13.26, I² = 0; Table 2, Supplementary figure 2-B, http://links.lww.com/MD/G72).

### 3.5.3. Bleeding volume.
In 3 studies, the bleeding volume after treatment was measured between the groups. The method and time point of measurement varied among studies. Therefore, we did not pool the results. Ruiz did not provide information regarding measurement of the bleeding volume and the variance of the effect sizes. They reported a significant reduction of bleeding volume after treatment with IV TXA. In the study by Bellam et al, the bleeding volume was measured on Day 1 and Day 2. They found that compared with the control, treatment with IV TXA reduced the bleeding volume on Day 1 (84.3 vs 145 mL) and Day 2 (34.19 mL/day vs 90.4 mL). In the study by Wand et al, the bleeding volume was measured as milliliters per 24 hours. The daily bleeding volume significantly reduced since Day 2 when patients were treated with TXA through nebulization compared with the placebo.

### 3.5.4. Length of stay.
Three studies (n = 19977) provided information on the hospital length of stay. Two studies used intravenous TXA and 1 study used nebulized TXA. The result showed that the length of stay was significantly shorter in the TXA group than in the control group (MD = -1.94 days, 95% CI = 2.48 to -1.40, I² = 0; Table 2, Supplementary figure 2-C, http://links.lww.com/MD/G72). A subgroup analysis was performed on two studies (n = 19930) using IV TXA. The result indicated that patients receiving IV TXA had a significantly shorter length of stay compared with those receiving the control (MD = -1.93 days, 95% CI = -2.49 to -1.37 days, I² = 0; Table 2, Supplementary figure 3, http://links.lww.com/MD/G73).

### 3.5.5. Need for intervention.
Two studies (n = 111) investigated whether patients with hemoptysis still required the intervention for hemostasis after medication. The procedure included surgery, bronchoscopy, or bronchial artery embolization. The pooled result revealed that TXA administration significantly reduced the need for intervention, compared with the controls (RR = 0.38, 95% CI 0.16–0.87, I² = 0; Table 2, Supplementary figure 2-D, http://links.lww.com/MD/G72).

### 3.5.6. Recurrence.
The recurrence of hemoptysis was assessed in 3 studies (n = 135). In 2 of these studies, TXA was administered through the IV route, and in 1 study, it was administered through nebulization. Hemoptysis recurring within 1 month or during the hospitalization was termed as short-term hemoptysis recurrence. A total of 5 of 81 (6.2%) patients who received TXA had short-term recurrent hemoptysis compared with 8 of 55 (14.5%) patients who received the control (RR = 0.40, Table 2, Supplementary figure 2-E, http://links.lww.com/MD/G72). However, the pooled results were not statistically different. Wand et al reported that patients administered TXA through nebulization had a significantly lower recurrence rate within 1 year compared with those administered the control (n = 47, 4% vs 22.7%, P < .01).

### 3.5.7. Safety.
No major complications, such as thromboembolic events, were observed in any of the clinical trials. In the large retrospective study, no significant difference was recorded in terms of thromboembolism (TXA 2.3% vs control 2.1%, P = .34) and seizure (TXA, 5/9933 cases vs control, 9/9933 cases). All clinical trials (n = 191) documented minor adverse effects associated with TXA, including nausea, dizziness, and gastrointestinal upset. The pooled result showed no significant difference

| Table 2 |
|---------------|----------------|----------------|----------------|--------|-------|
| **Outcome of interest** | **No. of studies** | **No. of patients** | **Effect sizes (95% CI)** | **P** | **I (%)** |
| **Cessation of bleeding** | 2 | 70 | RR = 1.44 (0.85 to 2.43) | .17 | 74 |
| **Time required to stop bleeding, h** | 2 | 70 | MD = –24.61 (–35.96 to –13.26) | <.05 | 0 |
| **Length of stay, days** | 3 | 19977 | MD = –1.93 (–2.49 to –1.37) | <.05 | 0 |
| **Length of stay (days), IV TXA subgroup** | 2 | 19930 | MD = –1.93 (–2.49 to –1.39) | <.05 | 0 |
| **Need for intervention** | 2 | 111 | RR = 0.38 (0.16 to 0.87) | <.05 | 0 |
| **Recurrence** | 3 | 135 | RR = 0.40 (0.12 to 1.28) | .12 | 0 |

IV = intravenous, MD = mean difference, RR = risk ratio, TXA = tranexamic acid.

* Statistically significant.
between TXA and control groups with regard to minor adverse effects (Supplementary Figure 4, http://links.lww.com/MD/G74).

4. Discussion

The principal finding of our study is that administration of TXA was associated with a reduction of the short-term mortality rate. IV administration of TXA also reduced short-term mortality in that subset of patients. Of noted, the pooled evidence driven from only RCTs also indicated that using TXA reduced the short-term mortality rate but this finding was statistically non-significant. Moreover, TXA use led to a shorter bleeding time, lower bleeding volume, shorter length of hospital stay, and less requirements for intervention compared with the control. Administration of TXA was not associated with the recurrence of hemoptysis or increase in major or minor adverse effects.

Expectoration of large amounts of blood is associated with high morbidity and mortality. Advances in medical imaging, fiberscope technology, and interventional radiology have led to improved outcomes, with the reporting mortality rates ranging from 7% to 30% since 2000. However, a strong recommendation regarding pharmacological treatment, such as antifibrinolytic agents for hemoptysis, does not exist. TXA is an antifibrinolytic agent that is commonly used to control bleeding, and it has recently been proven a promising strategy to reduce mortality from hemoptysis. Our study provided a comprehensive search from five databases and involved manual checking of the relative reviews and references to identify eligible studies. In total, 19,943 patients were included, a number that was significantly larger than that of patients in the latest systematic review (n = 617). We found that TXA administration consistently led to a 22% reduction in shorter-term mortality. Moreover, a consistent reduction in short-term mortality by 22% was observed in a subset of patients receiving IV TXA. Additionally, according to the study by Wand et al, treatment with TXA through inhalation reduced the long-term mortality by 2%. In accordance with our findings, previous large-scale clinical trials have demonstrated that administration of TXA reduced the mortality of patients during uncontrolled post-partum hemorrhage and traumatic bleeding. Of noted, the weight of the observational study was far larger than other RCTs in the current meta-analysis. The evidence based on only RCTs was not powerful to show the reduction on the short-term mortality. Therefore, more large-scale RCTs were warranted to clarify the issue.

Mild hemoptysis tends to stop spontaneously in some cases. For hemoptysis ≥1L per 24 hours, a mortality rate up to 58% was reported. Among cases of fatal hemoptysis, the inciting cause of death is asphyxiation from inability to oxygenate or ventilate because of the hemorrhage flooding the airways. The volume of the conducting airway is approximately 150 mL, and a nonsignificant amount of pulmonary bleeding may hinder oxygenation before hemodynamics becomes unstable. Therefore, it is critical to reduce the bleeding volume and foster bleeding cessation. Our study showed that patients in the TXA group showed earlier bleeding cessation by 24.3 hours compared with those in the control group. In addition, the results from three RCTs indicated that the administration of TXA reduced the bleeding volume. However, we did not observe any benefit of TXA in terms of the hemoptysis cessation rate. This could be attributed to the small number of the included studies with small sample sizes. Additional large clinical trials should be conducted to prove or disapprove our hypothesis.

The length of hospital stay is an important indicator of the patient quality of care and functional evaluation. Decreased length of hospital stay was associated with decreased medical costs in patients with hemoptysis. Our study demonstrated that administration of TXA significantly reduced the length of stay by 1.94 days. In consistency with our observation, TXA administration to patients suffering from truncal and peripheral vascular trauma led to a 4-day shortening of hospital period, compared with placebo. The explanation of this finding was that TXA provided better bleeding control, which may cause less morbidity during a hemoptysis episode, resulting in early discharge.

The requirement of embolization or surgical intervention to treat hemoptysis indicates additional medical efforts, risk of surgery, and anesthesia complications. A recent large RCT showed that TXA administration failed to reduce the requirement of surgical, endoscopic, or radiological intervention in patients with acute gastrointestinal bleeding. In contrast, TXA reduced the requirement for brace suture and laparotomy surgery in patients with postpartum hemorrhage. There is little evidence about the pharmacological effect of hemoptysis on the need for hemostasis intervention. In our study, we observed that TXA reduced the requirement of further interventions by 62%.

A major concern with the application of TXA was the increase of thromboembolic events. TXA is associated with more than 3-fold increased odds of venous thromboembolism in patients with trauma. Moreover, some studies showed that TXA administration led to a 6% to 11% increase in postoperative seizure among patients who underwent cardiac surgery. In addition, a case report had raised the concern that TXA administration led to pulmonary embolism in patients with chronic hemoptysis secondary to bronchiectasis. However, in our study, no increased major adverse events were observed in the included RCTs. Furthermore, TXA administration did not increase the incidence of thromboembolic events and seizure in a large-scale included observational study. Therefore, TXA seemed safe for hemoptysis control.

Although our meta-analysis demonstrated the benefit of TXA for hemoptysis, it has several limitations. First, limited studies were included and the case numbers of the RCTs involved were relatively small. Second, observational studies were also included, which could have introduced a selection bias. Third, the length of treatment, dosage, and form of TXA administration, and the definition of severity of hemoptysis varied among the studies, which may introduce clinical heterogeneities. However, significant statistical heterogeneities were observed only at the analysis of the hemoptysis cessation rate. Fourth, some factors, such as smoking, malignancy, pulmonary infection, and anti-coagulant drug use, were associated with increased rate of mortality and hemoptysis recurrence. These confounding factors were not fully disclosed in some studies (Supplementary Table 3, http://links.lww.com/MD/G77). Moreover, most of the studies included all etiologies of hemoptysis, except one study that specifically dealt with tuberculosis-related hemoptysis. Therefore, whether the results of our study could be generalized to a specific population warrants further investigation. Finally, a funnel plot for assessing publication bias was not depicted owing to the small number of studies included.

5. Conclusions

Our meta-analysis indicated that administration of TXA was associated with a reduction of short-term mortality rate, shorter time required to stop bleeding, shorter length of hospital stays,
and less requirement of intervention among patients with hemoptysis. TXA is considered a safe medication for hemoptysis. TXA is associated with less requirement of intervention among patients with hemoptysis.

Author contributions
Liang-Fu Chen, Ting-Cheng Wang, and Yuan-Pin Hsu had full access to all data in the study and take responsibility for data integrity and accuracy of data analysis.

Acquisition, analysis, or interpretation of data: Liang-Fu Chen, Ting-Cheng Wang, Chih-Hao Yang, Ting-Yi Lin, Po-Jia Pao, Karen Chia-Wen Chu, and Jer-Hwa Chang.

Concept and design: Liang-Fu Chen and Yuan-Pin Hsu.

Data curation: Liang-Fu Chen, Po-Jia Pao.

Drafting of manuscript: Liang-Fu Chen, Ting-Cheng Wang and Yuan-Pin Hsu.

Investigation: Liang-Fu Chen, Ting-Yi Lin, Po-Jia Pao, Karen Chia-Wen Chu, Chih-Hao Yang.

Resources: Ting-Cheng Wang, Chyi-Huey Bai.

Statistical analysis: Chih-Wang Hsu and Chyi-Huey Bai.

Study supervision: Ting-Cheng Wang and Yuan-Pin Hsu.

Supervision: Ting-Cheng Wang, Jer-Hwa Chang, Chin-Wang Hsu, Yuan-Pin Hsu.

Writing – original draft: Liang-Fu Chen, Ting-Cheng Wang, Karen Chia-Wen Chu.

Writing – review & editing: Yuan-Pin Hsu.

References

[1] Mondoni M, Carlucci P, Job S, et al. Observational, multicentre study on the epidemiology of haemoptysis. Eur Respir J 2018;51:

[2] Hirshberg B, Biran I, Glazer M, et al. Haemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997;112:440–4.

[3] Sakr L, Dutau H. Massive haemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respiration 2010;80:38–58.

[4] Dweik RA, Stoller JK. Role of bronchoscopy in massive haemoptysis. Clin Chest Med 1999;20:89–105.

[5] Abdulmalak C, Cottenet J, Beltramo G, et al. Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database. Eur Respir J 2015;46:503–11.

[6] Petersen CL, Weinreich UM. Five-year follow-up of haemoptysis with no malignancy suspected on chest computed tomography: recurrence, lung cancer and mortality. Eur Clin Res J 2019;6:161519.

[7] Earwood JS, Thompson TD. Haemoptysis: evaluation and management. Am Fam Phys 2015;91:243–9.

[8] Shakur H, Roberts I, Favole B, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017;389:2105–16.

[9] Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23–32.

[10] Gaillard S, Dupuis-Girod S, Boutitie F, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost 2014;12:1494–502.

[11] Prutsky G, Domecq JP, Salazar CA, et al. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database Syst Rev 2012;CD008711.

[12] Prutsky G, Domecq JP, Salazar CA, et al. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database Syst Rev 2016;CD008711.

[13] Tsai Y-S, Hsu L-W, Wu M-S, et al. Effects of tranexamic acid on haemoptysis: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Invest 2020;40:789–97.

[14] Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009;6:e1000097.

[15] Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.

[16] Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2021. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed May 4, 2021.

[17] Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557.

[18] Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629.

[19] Ruiz W. Acido Tranexamico vs Placebo en Hemoptisis por TBC Pulmonar: Estudio Piloto Doble Ciego [PhD thesis]; 1994.

[20] Tscheikuna J, Chvaychoo B, Naruman C, et al. Tranexamic acid in patients with hemoptysis. J Med Assoc Thai 2002;85:399–404.

[21] Bellam BL, Dhibar DP, Suri V, et al. Efficacy of tranexamic acid in haemoptysis: a randomized, controlled pilot study. Pulm Pharmacol Ther 2016;40:80–3.

[22] Wand O, Guber E, Guber A, et al. Inhaled tranexamic acid for hemoptysis treatment: a randomized controlled trial. Chest 2018;154:1379–84.

[23] Alberto-Pasco C, Soto A. Association of tranexamic acid to mortality and blood transfusion among patients with hemoptysis at Hipolito Unanue Hospital of Lima, Peru. Rev Peru Med Exp Salud Publica 2013;30:537–8.

[24] Kinoshita T, Ohbe H, Matsui H, et al. Effect of tranexamic acid on mortality in patients with haemoptysis: a nationwide study. Crit Care 2019;23:347.

[25] Fartoukh M, Khoshnood B, Parrot A, et al. Early prediction of inhospital mortality of patients with hemoptysis: an approach to defining severe hemoptysis. Respiration 2012;83:106–14.

[26] Ong TH, Eng P. Massive haemoptysis requiring intensive care. Intensive care medicine 2003;29:317–20.

[27] Razazi K, Parrot A, Khalil A, et al. Severe haemoptysis in patients with nonsmall cell lung carcinoma. Eur Respir J 2015;45:756–64.

[28] Moen CA, Burrell A, Dunning J. Does tranexamic acid stop haemoptysis? Interact Cardiovasc Thorac Surg 2013;17:991–4.

[29] Gadre A, Stoller JK. Tranexamic acid for empyema: a review. Clin Pulm Med 2017;24:69–74.

[30] Adams TR, Reeder JA, Alqassab F, et al. Inhaled TXA for cases of massive haemoptysis. Am J Emerg Med 2020;38:156–7.

[31] Corey R9, Hla KM. Major and massive haemoptysis: reassessment of conservative management. Am J Med Sci 1987;294:301–9.

[32] Davidson K, Shojae S. Managing massive haemoptysis. Chest 2020;157:77–88.

[33] Patwa A, Shah A. Anatomy and physiology of respiratory system relevant to anaesthesia. Indian J Anaesth 2015;59:533–41.

[34] Advanced trauma life support (ATLS®): the ninth edition. J Trauma Acute Care Surg 2013;74:1363–6.

[35] Gnanadev R, Dong F, Ali A, et al. RS12. Comparing mortality and hospital length of stay in the setting of truncal and peripheral vascular trauma in patients treated with tranexamic acid on initial presentation. J Vasc Surg 2019;69:e188–9.

[36] Roberts I, Shakur-Still H, Afolabi A, et al. Effects of high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020;395:1927–36.

[37] Myers SP, Kucher ME, Rosengart MR, et al. Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. J Trauma Acute Care Surg 2019;86:20–7.

[38] Berman M, Cardone D, Sharples L, et al. Safety and efficacy of aprotinin and tranexamic acid in pulmonary endarterectomy surgery with hypothermia: review of 200 patients. Ann Thorac Surg 2010;90:1432–6.

[39] Keyl C, Uhl R, Beyersdorf F, et al. High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg 2011;39:e114–21.

[40] Krivokuca I, Lammers JW. Recurrent pulmonary embolism associated with a hemostatic drug: tranexamic acid. Clin Appl Thromb Hemost 2011;17:106–7.

[41] Seki N, Go S, Mayuko O, et al. Risk factors for a second episode of hemoptysis, clinical medicine. Circulatory, Respiratory and Pulmonary Medicine 2009;3:1–7.

[42] Lee MK, Kim SH, Yong SJ, et al. Moderate hemoptysis: recurrent hemoptysis and mortality according to bronchial artery embolization. Clin Respir J 2015;9:53–64.

[43] Choi J, Baik JH, Kim CH, et al. Long-term outcomes and prognostic factors in patients with mild hemoptysis. Am J Emerg Med 2018;36:1160–5.